Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEurocell Regulatory News (ECEL)

Share Price Information for Eurocell (ECEL)

Share Price is delayed by 15 minutes
Get Live Data
109.00    -2.00 (-1.80%)
Bid:
104.00
Ask:
107.00
Spread: 3.00 (2.885%)
Market Cap: £107.42m
ECEL Live PriceLast checked at - London Stock Exchange

Intraday Eurocell Share Chart

Trading Update

14 May 2026 07:00

RNS Number : 2218E
Eurocell plc
14 May 2026
 

14 May 2026

EUROCELL PLC

("Eurocell" the "Group" or the "Company")

Trading Update

 

Eurocell plc, the leading UK manufacturer and distributor of window and door products to the trade, provides the following update for the first four months of 2026, in advance of the Annual General Meeting ("AGM") later today.

 

Summary

Trading conditions have remained subdued in 2026. Ongoing challenging macroeconomic conditions and weak consumer confidence have been compounded by uncertainty over the impact of conflict in the Middle East on demand and supply chains. This has continued to affect activity levels in both the repair, maintenance and improvement (RMI) market and new build housing.

 

To mitigate the impact of weak markets and the situation in the Middle East, we continue to invest in and progress our strategic initiatives, implement operational improvements, focus on cost control and offset the impact of higher input cost prices through a combination of surcharges and sales strategies.

 

However, the effect of this backdrop on consumer confidence and new build housing market activity over the near term remains difficult to assess, which is reflected in the range of analysts' forecasts for the year(1).

 

(1) Company compiled range of analysts' forecast adjusted profit before tax for the year of £21 million to £23 million.

 

Trading Performance

Group sales for the four months to 30 April 2026 were up 9%(2) on 2025. Excluding Alunet, sales were up 1%(2), with an improvement to +5%(2) for the month of April. Comparisons by division for the four-month period were:

 

Sales to 30 April 2026

vs 2025(2)

Profiles Division

-4%

Branch Network Division

+5%

Group, excluding Alunet

+1%

Total Group, including Alunet

+9%

(2) On a trading day adjusted basis

 

Profiles - sales down 4%, reflecting reduced RMI activity through our trade fabricators, and persistent wet weather in the first quarter, with new build and social housing fabricators reporting a lack of call-off activity from their customers.

 

Branch Network - sales up 5%, reflecting:

· Underlying Branch Network sales to the RMI market down 3%

· Offset by the benefits of progress with our strategic initiatives for window and door sales (up 29%), e-commerce activity (up 40%), and garden rooms (up 6%)

· The nine new branches opened since the end of 2024 have delivered incremental sales of £1.1 million so far in 2026, compared to the corresponding period in 2025

 

New branches create a short-term drag on profitability but enable longer-term profit improvement. Whilst we have identified further potential new sites, we have temporarily paused the opening programme until there is better visibility over the general economic outlook.

 

Alunet (acquired in March 2025) - continues to perform strongly, driven by market share gains.

 

Alunet sales were £18.6 million for the 4 months to 30 April 2026, compared to £8.3 million for the 2-month post-acquisition period to 30 April 2025. On a calendar basis, Alunet sales for the 4 months to 30 April 2026 were 19% ahead of the corresponding period in 2025, reflecting:

· Alunet Systems new business with fourteen Eurocell fabricators, plus launch of the new Aluna+ aluminium window system 

· Comp Door continuing to acquire new installers, plus impact of the new Sleekskin door and benefits from cross selling opportunities through the Branch Network

 

As a result of Alunet's strong EBITDA delivery, we expect to make earnout payments shortly of c.£4 million in respect of its 2025 performance.

 

Capital Allocation

In line with our strategic plan, further investments in the next 12 months include delivering the project to modernise our IT infrastructure, where we expect to transition at the end of 2026.

 

We are committed to driving shareholder returns through a combination of ordinary dividends and supplementary distributions where appropriate. Total shareholder returns for 2025 were £11.4 million, equivalent to a yield of c.8%. This follows total returns for 2024 of £21.2 million, equivalent to a yield of c.14%.

 

As previously announced, our intention remains to continue share buybacks in due course, assuming no prolonged impact from the situation in the Middle East and subject to maintaining a strong financial position.

 

Our balance sheet is strong, and we have good headroom on our debt facility, which was renewed in March 2026.

 

 

Enquiries:

Eurocell plc

Will Truman, Chief Executive Officer +44 (0) 1773 842 105

Michael Scott, Chief Financial Officer +44 (0) 1773 842 140

Teneo

Nick de Bunsen +44 (0) 7825 575 258

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBUGDUUSBDGLX
Date   Source Headline
18th May 20264:00 pmRNSDirector/PDMR Shareholding
14th May 20261:49 pmRNSResult of AGM
14th May 20267:00 amRNSTrading Update
1st May 20267:00 amRNSDirector/PDMR Shareholding
17th Apr 20267:00 amRNSLeadership Update - CFO Appointment
15th Apr 20267:00 amRNSPublication of 2025 Annual Report & Notice of AGM
23rd Mar 202610:15 amRNSDirector/PDMR Shareholding
19th Mar 202610:30 amRNSDirector/PDMR Shareholding
19th Mar 20267:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2025
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
16th Mar 20267:00 amRNSNotice of Results and Investor Presentation
17th Feb 20267:00 amRNSTransaction in Own Shares - Buyback Complete
16th Feb 20267:00 amRNSTransaction in Own Shares
13th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20261:00 pmRNSDirectorate changes
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSDirector/PDMR Shareholding
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTransaction in Own Shares
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSYear End Trading Update
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20267:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
5th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20257:00 amRNSTransaction in Own Shares
3rd Dec 20254:00 pmRNSPurchase of Shares via Employee Benefit Trust
3rd Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.